Emcure Pharmaceuticals Ltd.
NSE: EMCUREEmcure Pharmaceuticals Ltd.: A 30-second snapshot
Emcure Pharmaceuticals trades at Rs 1,704.90, up 66.95% over the past 12 months, above both its 50-DMA (Rs 1,585.61) and 200-DMA (Rs 1,456.02), with a trailing PE of 34.99 compressing to a forward PE of 22.90. FY26 revenue crossed $1 billion and PAT grew 33% YoY, but the balance sheet carries a debt-to-equity ratio of 30.57 — substantially elevated relative to the sector — even as the debt trend is classified as falling. Two regulatory and reputational risk events emerged in May 2026: 7 US FDA observations at the Sanand facility and a social-media controversy linked to a company director.
P/E
35.0
Forward P/E
22.9
ROE
+19.6%
Debt / Equity
30.57
Profit Margin
+10.0%
Div. Yield
+0.2%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
68/100
News
8 headlines · 1 positive · 4 negative
Emcure Pharma receives 7 US FDA observations for Sanand formulations facility in Gujarat - CNBC TV18
CNBC TV18
Emcure Pharma shares slide 6% post-Q4 results on profit booking - TradingView
TradingView
Emcure FY26 Results: Revenue Crosses $1 Bn, PAT Up 33% - scanx.trade
scanx.trade
Emcure Pharma stock falls amid Namita Thapar's 'namaz health benefits' video row, products boycott 'call' - MSN
MSN
Mauritius-based entity sells Rs 289 crore worth shares in Emcure Pharmaceuticals via block deal; Norges Ba - The Economic Times
The Economic Times
Recent context
- ·FY26 full-year results (reported May 5, 2026) showed revenue crossing $1 billion and PAT up 33% YoY; the initial share price reaction was a 6% decline attributed to profit booking against elevated pre-result positioning.
- ·The US FDA issued 7 observations for the Sanand (Gujarat) formulations facility on May 16, 2026 — the most operationally material risk item in recent news flow given the potential for production-level consequences if observations are not resolved satisfactorily.
- ·A Mauritius-based entity sold Rs 289 crore worth of shares via a block deal (April 29, 2026), with Norges Bank cited as the acquiring counterparty; institutional block deals of this size can reflect portfolio rebalancing, but the directional ownership shift is notable.
Strengths
- +Highest ROE among ranked sector peers at 19.57%, with 4 of 5 years above the 15% threshold and a consistency score of 98 — indicating profitability has been sustained rather than episodic.
- +5-year revenue CAGR of 16.7% and 5-year earnings CAGR of 28.8% show earnings growing faster than revenue over the period, a marker of expanding margins.
- +Trailing PE of 34.99 compresses to a forward PE of 22.90, a 35% forward discount against recent PAT growth; FCF was positive in 4 of the last 5 years, supporting earnings quality.
- +Highest quality score (54) among the 6 ranked sector peers, above SUNPHARMA (50), CIPLA (24) and DRREDDY (17), indicating relatively stronger composite fundamentals within this peer set.
Weaknesses
- −Debt-to-equity of 30.57 is the primary structural risk on this balance sheet; even with a falling debt trend, this level is materially above most pharma comparables and creates sensitivity to interest-rate changes and refinancing conditions.
- −7 US FDA observations at the Sanand formulations facility (reported May 16, 2026) introduce regulatory uncertainty for a key manufacturing site; unresolved observations can escalate to warning letters or import restrictions.
- −Profit margin of 10.04% is modest for a pharma business of this scale; combined with high leverage, it limits the buffer available to absorb adverse cost or pricing shocks.
- −The stock fell approximately 6% immediately after Q4 results despite 33% PAT growth, suggesting the market had priced in a higher outcome; this gap flags elevated expectations embedded in the current valuation.
Open questions
- ?How much of the 30.57 D/E ratio reflects operating leverage built into the pharma distribution model versus long-term debt that needs to be serviced from operating cash flows, and what is the interest coverage ratio at current earnings levels?
- ?The 7 US FDA observations at Sanand: what is the historical resolution timeline for FDA observations at comparable Indian pharma facilities, and what share of Emcure's US revenue is routed through this specific facility?
- ?The forward PE of 22.90 implies meaningful earnings growth is already priced in — if earnings growth in FY27 comes in at or below consensus, how does the current valuation compare to sector peers on a normalised basis?
- ?Does the 5-year ROE persistence of 19.57% reflect a structural competitive position in Emcure's therapeutic segments, or is it partly a function of the same financial leverage that produces the elevated D/E ratio?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| EMCURE | Emcure Pharmaceuticals Ltd.You're viewing | 35.0 | +19.6% | 54 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.4 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.7 | +11.8% | 17 |
Technical state
Current price
₹1,704.90
SMA 50
₹1,585.61
SMA 200
₹1,456.02
RSI (14)
57.3 (neutral)
From 52w high
-6.8%
1Y return
+67.0%
3M return
+12.9%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highDebt-to-equity of 30.57 is far above typical pharma company norms; even with debt trend noted as falling, this level implies significant interest burden and refinancing exposure relative to the sector.
- medium7 US FDA observations received for the Sanand formulations facility (Gujarat) as of May 2026; regulatory observations at a manufacturing site carry potential for import alerts or production disruptions if unresolved.
- mediumA social-media controversy involving a company director (viral video row, products boycott call) generated 4 of 8 recent news items classified negative; the concentration of negative sentiment in a small news sample elevates reputational risk visibility.
- lowPeer ROE and 1-year price-change data are missing for 4 of 5 listed peers, limiting the reliability of sector-relative rankings on those dimensions.
Cross-section contradictions
- ROE of 19.57% with 4 of 5 years above 15% and a consistency score of 98 reflects durable operational profitability, yet a D/E of 30.57 — an order of magnitude above most listed pharma peers — sits alongside that record as a structural leverage risk that operating returns alone do not resolve.
- News sentiment is negative (4 negative vs 1 positive of 8 total) yet the stock is up 66.95% over 12 months, trading above both its 50-DMA and 200-DMA; the market price action and fundamental earnings trajectory have not reflected the adverse news flow.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 24 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days